Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povetacicept versus tacrolimus in primary membranous nephropathy
CTR20253958Phase 3Active
- Sponsor
- ——/ 再鼎医药（上海）有限公司
- Start
- Dec 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of povetacicept in idiopathic membranous glomerulonephritis (IMG), sponsored by ——/ 再鼎医药（上海）有限公司. Started Dec 2025; status: active.
02
Drugs
povetacicept
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on CTR20253958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253958.